Last update 8/2023

			Novelty				Development Stage				
AMR Accelerator Project	**Asset Owner**	**Programme**	**New Class**	**New MoA**	**Mode of Action (MoA)**	**Description**	**Discovery**	**(Pre)-Hit to Lead**	**Lead to Candidate**	**Candidate to Phase I**	**Phase I**
GNA NOW €31 m	NOSOPHARM	NOSO-502	✓	✓	Inhibition bacterial ribosome	NOSO-502 is the first clinical candidate in the novel antibiotic class called Odilhorhabdins, inhibiting the bacterial ribosome with a new mechanism of action.				■	
TRIC-TB €8 m	BioVersys and GSK	Boosting Ethionamide	✓	✓	Transcriptional modulator	Boosting Ethionamide efficacy and lowering the dose with small molecule transcriptional modulators to overcome multi-drug resistant tuberculosis infections and define a new place for Ethionamide in 1st-line TB treatments.					■
AB-Direct €4 m	GSK	Gepotidacin tissue distribution	✓	✓	Topoisomerase type II inhibitor	Demonstrating penetration of gepotidacin in tonsillar and prostate tissues.					■
ERA4TB €208 m		ERA4TB-01	✓	✓	Cholesterol catabolism of mycobacteria	Molecule targeting cholesterol catabolism of mycobacteria.					■
		ERA4TB-02	✓	✓	Mycobacterium tuberculosis tryptophan synthase	Compound targeting Mycobacterium tuberculosis tryptophan synthase, enzyme that catalyses the final two steps in the biosynthesis of tryptophan.			■		
		ERA4TB-03			Energy metabolism	Compounds targeting energy metabolism (electron chain transport).					■
		ERA4TB-04	✓	✓	Lysine transfer RNA synthase	Compound targeting lysine transfer RNA synthase (Rv3598c), which is an essential gene as assessed by transposon mutagenesis.			■		
		ERA4TB-06	✓	✓	Mycobacterial membrane protein Large 3	Mycobacterial membrane protein Large 3 compounds with potent in vitro inhibitory and bactericidal activity against Mycobacterium tuberculosis.			■		
		ERA4TB-09	✓	✓	/	Natural product analogs active against Mycobacterium tuberculosis.			■		
		ERA4TB-10	✓	✓	Enzyme DprE1	Piperazinobenzothiazinone derivative as anti-mycobacterial compound that targets and covalently inhibits the enzyme Decaprenyl-phosphoryl-ribose 2'-epimerase.					■
RespiriTB & NTM €10 m (TB) €8 m (NTM)	JANSSEN	BC1 back up	✓	✓	BC1	Lead optimization program on BC1 inhibitor.			■		
		RespiriTB	✓	✓	Mycothiane reductase	Mycothione reductase target exploration.	■				
		RespiriNTM			/	Progress novel assets (one First-in-human start) for Non-Tubercular Mycobacterium (NTM) that may act synergistically with Bedaquiline and cytochrome bc Drugs.		■			
UNITE4TB €185 m	TBA										

Accelerating scientific discoveries in the antimicrobial resistance (AMR) field

COMBINE €25 m	Providing learnings derived from shared vaccine and/or antibacterial clinical trial data and improving understanding of variability and translatability of animal models of bacterial infection.
PrIMAVeRa €9 m	Developing a decision-making tool accessing health and economic outcomes of vaccines on the reduction of AMR.